These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. Guarino E, Nigi L, Patti A, Fondelli C, Dotta F. Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507 [Abstract] [Full Text] [Related]
4. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Deacon CF, Mannucci E, Ahrén B. Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248 [Abstract] [Full Text] [Related]
6. [Significance of combination therapy with an insulin sensitizer and a DPP-4(dipeptidyl peptidase-4) inhibitor]. Yasuda T, Shimomura I. Nihon Rinsho; 2013 Mar; 71(3):555-62. PubMed ID: 23631252 [Abstract] [Full Text] [Related]
7. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors. Kumar A. Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862 [Abstract] [Full Text] [Related]
8. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. van Genugten RE, van Raalte DH, Diamant M. Diabetes Obes Metab; 2012 Feb; 14(2):101-11. PubMed ID: 21752172 [Abstract] [Full Text] [Related]
10. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Pratley RE, Salsali A. Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649 [Abstract] [Full Text] [Related]
11. Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence? Charbonnel B, Schweizer A, Dejager S. Hosp Pract (1995); 2013 Apr; 41(2):93-107. PubMed ID: 23680741 [Abstract] [Full Text] [Related]
19. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Mulherin AJ, Oh AH, Kim H, Grieco A, Lauffer LM, Brubaker PL. Endocrinology; 2011 Dec; 152(12):4610-9. PubMed ID: 21971158 [Abstract] [Full Text] [Related]
20. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients? Halimi S. Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591 [Abstract] [Full Text] [Related] Page: [Next] [New Search]